Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
Business Wire India Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free…